drugset / Trial / NCT01932151

Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis

NCT01932151

Completed 18 enrolled Hospital Clinic of Barcelona
NaSingle-groupOpen-labelTreatment

Summary

Type 1 Hepatorenal syndrome (type-1 HRS) is a severe complication of patients with advanced cirrhosis characterized by marked renal failure and is associated with a very poor prognosis. Type-1 HRS is often precipitated by a bacterial infection, though it may occur spontaneously. It has been demonstrated that vasoconstrictor agents plus albumin are effective in the reversal of the renal failure. A large number of studies have shown that terlipressin improves renal function in patients with type 1 HRS; treatment is effective in 50-75% of patients approximately. Currently there are no specific studies about the treatment of type-1 HRS with ongoing infections.

Timeline

Start
2012-12
Primary completion
2013-07
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 40 g
Subject Terlipressin Peptide 1 mg Intravenous
Subject Terlipressin Peptide 2 mg Intravenous

Indications